Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.
Title | Statins and Type 2 Diabetes Mellitus: An Update After 1 Year. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. |
Journal | Curr Pharm Des |
Volume | 22 |
Issue | 18 |
Pagination | 2723-5 |
Date Published | 2016 |
ISSN | 1873-4286 |
Keywords | Diabetes Mellitus, Type 2, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Abstract | In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data. |
Alternate Journal | Curr. Pharm. Des. |
PubMed ID | 26806344 |